Literature DB >> 26616150

Meta-analysis of transforming growth factor β receptor I 6A/9A gene polymorphism and breast cancer risk: the picture remains murky.

Chao Ou1, Hang Li2, Jiang-Hua Liu3, Gregor P C Drummen4, Bo Zhu1, Ling-Sha Huang1, Ying Huang1, Le-Qun Li5.   

Abstract

Breast cancer is currently the second most common cancer worldwide and the most frequent malignant tumor among women. However, the exact contribution of various allelic alterations remains unclear. This meta-analysis was conducted to evaluate the association of the transforming growth factor β receptor I 6A/9A (TβR-I 6A/9A) gene polymorphism with breast cancer risk. Relevant studies were identified from PubMed and Cochrane Library on 1 October 2013, and eligible reports were recruited and synthesized. Eleven reports that included a total of 12 studies were recruited into this meta-analysis for the association of the TβR-I 6A/9A gene polymorphism and breast cancer risk. The results indicated that overall the TβR-I 6A allele was associated with breast cancer risk (OR = 1.33, 95% CI: 1.02-1.73, p = 0.04). However, the TβR-I 6A/6A and 9A/9A genotypes were not associated with an increased risk of developing breast cancer (6A/6A: OR = 1.71, 95% CI: 0.95-3.08, p = 0.07; 9A/9A: OR = 0.82, 95% CI: 0.66-1.02, p = 0.08). In the Caucasian population, no such association could be established. In conclusion, the TβR-I 6A allele might represent a risk factor for breast cancer risk, but significantly larger data sets from a larger number of studies, including studies that allow ethnicity, subgroup analysis and environmental impact evaluation, are required to maximize statistical significance and meta-analysis robustness.

Entities:  

Keywords:  6A/9A; breast cancer; gene polymorphism; meta-analysis; transforming growth factor β receptor I

Mesh:

Substances:

Year:  2015        PMID: 26616150     DOI: 10.3109/1354750X.2015.1096307

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  2 in total

Review 1.  TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects.

Authors:  Kojo Agyemang; Allan M Johansen; Grayson W Barker; Michael J Pennison; Kimberly Sheffield; Hugo Jimenez; Carl Blackman; Sambad Sharma; Patrick A Fordjour; Ravi Singh; Katherine L Cook; Hui-Kuan Lin; Wei Zhang; Hui-Wen Lo; Kounosuke Watabe; Peiqing Sun; Carl D Langefeld; Boris Pasche
Journal:  NPJ Breast Cancer       Date:  2022-07-19

2.  Body Composition Analysis of 10 Years versus 5 Years of Adjuvant Endocrine Therapy in Patients with Nonmetastatic Breast Cancer.

Authors:  Ruyi Hu; Xinran Cheng; Jun Liu; Xu Lai; Ruifeng Wang; Dongchang Yu; Yanan Fan; Zhaoshi Yu
Journal:  J Oncol       Date:  2021-01-16       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.